Samrat Pharmachem Ltd.
Snapshot View

266.90 -1.95 ▼-0.7%

23 July 2021, 04:00:00 P.M.
Volume: 2,059

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.samratpharmachem.com
Financial Indicators
Market Cap 81.43 Cr.
Earnings per share (EPS) 17.26 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 15.27 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 95.92 Trailing Twelve Months Ending 2021-03
Price to Book Value 2.75 Calculated using Price: 263.55
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.31 Cr. 3,089,700 Shares
FaceValue 10
Company Profile

Samrat Pharmachem was incorporated on June 16, 1992, at Ankleshwar in Gujarat. It was promoted by Lalit Mehta & Rajesh Mehta. The company is currently manufacturing iodine salts & bromine salts. The finished products produced by the company are used in various industries like Pharmaceuticals, Chemicals, Food, Fertilizer, Salt, etc. The products of the company are well received in Indian & foreign markets. The company is a public limited company & its shares are listed & traded on the Bombay Stock Exchange & other bourses of India. The company is presently employing 30 people for its operations at Ankleshwar & Mumbai.

The company’s manufacturing unit & test laboratory is situated in Ankleshwar. The factory is spread in an area of 3645 sq. mtrs. & has a constructed area of 20000 sq. ft. Technical innovation is their core strength. If anything is possible chemically, they strain their nerves to make it a reality. Research & Development is multi faceted focusing both on product & process development. Their commitment to keep the atmosphere beautiful & pure inspires them for further improvement in the process techniques.

The company is having a modern & well equipped quality control laboratory manned by experienced professionals who have set high standards for testing & approval. Starting with the raw materials, the intermediate stages & right upto the final stage, the products are continuously monitored for quality. The company's products & laboratory is approved by the Food & Drug Administration, Gandhinagar, Gujarat.

Samrat is well equipped to discharge its function round the year without any breakdown under adverse conditions. The company has fully computerized, centrally located office in the heart of Mumbai. Excellent documentation & personal attention to all national & international order ensures smooth & flawless logistical services. The company has well trained staff to meet any contingencies. Safe, convenient & tamper proof packaging ensures easy handling & reliability.The company is heading towards being accredited ISO 9000 & ISO 14000 Certification shortly.

The company is heading towards ERP implementation, which will integrate all the activities of the company on the internet thereby giving speedy information & reports.

Product range of the company includes:

Samrat has a major chunk of the business in Iodine & Bromine Salts. The company's customers include several multinational companies in India & Abroad. The company is exporting a part of its products to USA, Europe, Japan etc.

  • Calcium Iodate Monohydrate
  • Copper Iodide
  • Hydriodic Acid 47% 
  • Hydriodic Acid 57%
  • Iodine 
  • Iodine Monochloride
  • Iodoethane (Ethyl iodide)
  • Iodomethane (Methyl iodide)
  • Potassium Bromide
  • Potassium Iodate
  • Potassium Iodide
  • Potassium Metaperiodate
  • Sodium Iodate
  • Sodium Iodide
  • Sodium Metaperiodate
  • Trimethyl Sulfoxoniumiodide

Achievements/ recognition :

  • The company's products & laboratory is approved by the Food & Drug Administration, Gandhinagar, Gujarat.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.73%
1 Week
+1.06%
1 Month
+11.35%
3 Month
+42.77%
6 Month
+115.24%
1 Year
+180.36%
2 Year
+270.69%
5 Year
+734.06%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 35.61 3.15 1.86 2.38 2.21 12.07 19.01 7.96 19.10
Return on Capital Employed (%) 48.84 9.25 6.93 6.45 5.31 16.40 23.05 11.80 22.43
Return on Assets (%) 15.02 1.22 0.74 1.10 0.97 4.86 8.37 3.79 8.60

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 13 13 13 13 14 15 19 20 24
Non Curr. Liab. 2 1 1 1 2 2 1 1 0
Curr. Liab. 17 20 17 12 20 19 21 19 34
Minority Int.
Equity & Liab. 32 34 31 26 36 36 41 40 58
Non Curr. Assets 7 8 8 8 8 8 8 7 9
Curr. Assets 25 26 24 18 28 28 33 33 50
Misc. Exp. not W/O
Total Assets 32 34 31 26 36 36 41 40 58

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 71 72 66 48 63 73 93 111 137
Other Income 0 1 1 0 0 0 0 0 1
Total Income 71 73 67 49 63 73 93 112 138
Total Expenditure -65 -71 -66 -47 -62 -69 -87 -108 -131
PBIDT 7 2 1 2 1 4 6 4 7
Interest -1 -1 -1 -1 -1 -1 -1 -1 -1
Depreciation 0 0 0 0 0 0 0 0 0
Taxation -2 0 0 0 0 -1 -2 -1 -2
Exceptional Items 0 0
PAT 4 0 0 0 0 2 3 2 4

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 4 -2 4 -1 0 -3 0 2 -1
Cash Fr. Inv. -4 -1 0 0 -2 1 -2 2 -2
Cash Fr. Finan. 2 1 -1 0 2 1 2 -4 2
Net Change 2 -2 2 0 0 -1 -1 1 -1
Cash & Cash Eqvt 2 0 2 2 4 2 1 2 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 49.13 49.13 49.13 49.13 49.13 49.13 49.13 49.30 49.30
Public 50.87 50.87 50.87 50.87 50.87 50.87 50.87 50.70 50.70
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021
Samrat Pharmachem Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Thu, 15 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
We enclose herewith the Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended June 30 2021 received from M/s. Link Intime India Pvt. Ltd. (RTA) for your information and record.
Thu, 15 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Nishant Kankaria
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Fri, 23 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Close Within 2 Year High Zone Close Within 2 Year High Zone
Close Within 5 Year High Zone Close Within 5 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
ATR Decreasing for 3 Days ATR Decreasing for 3 Days

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%